Weekly · monthly · quarterly news summaries, side by side in time
Securities fraud lawsuits pile up ahead of August 10 deadline Multiple law firms filed or reminded investors of class actions alleging ADMA hid a related-party deal and used channel stuffing to inflate revenue. The August 10 lead-plaintiff deadline keeps legal risk and uncertainty in focus, weighing on the stock.
This is the main new development this period and directly pressures ADMA's price through legal risk.
Securities fraud lawsuits pile up ahead of August 10 deadline Multiple law firms filed or reminded investors of class actions alleging ADMA hid a related-party deal and used channel stuffing to inflate revenue. The August 10 lead-plaintiff deadline keeps legal risk and uncertainty in focus, weighing on the stock.
This is the main new development this period and directly pressures ADMA's price through legal risk.
Securities fraud lawsuits pile up ahead of August 10 deadline Multiple law firms filed or reminded investors of class actions alleging ADMA hid a related-party deal and used channel stuffing to inflate revenue. The August 10 lead-plaintiff deadline keeps legal risk and uncertainty in focus, weighing on the stock.
This is the main new development this period and directly pressures ADMA's price through legal risk.
Securities fraud class actions pile up Multiple law firms filed class actions alleging ADMA hid a related-party deal and used channel stuffing to inflate revenue, with a lead plaintiff deadline of August 10, 2026. These lawsuits keep legal risk and uncertainty in focus, weighing on the stock.
This is the main new event of the period and directly pressures ADMA's price through legal and reputational risk.
Underlying business still growing ADMA reported 28% year-over-year revenue growth from ASCENIV last quarter and is advancing SG-001, a hyperimmune globulin candidate, while new manufacturing efficiencies expand margins. This shows the core business remains healthy despite the legal cloud.
It provides the real counterweight to the negative legal news, showing why the stock isn't only about lawsuits.
Securities fraud class actions pile up Multiple law firms filed class actions alleging ADMA hid a related-party deal and used channel stuffing to inflate revenue, with a lead plaintiff deadline of August 10, 2026. These lawsuits keep legal risk and uncertainty in focus, weighing on the stock.
This is the main new event of the period and directly pressures ADMA's price through legal and reputational risk.
Underlying business still growing ADMA reported 28% year-over-year revenue growth from ASCENIV last quarter and is advancing SG-001, a hyperimmune globulin candidate, while new manufacturing efficiencies expand margins. This shows the core business remains healthy despite the legal cloud.
It provides the real counterweight to the negative legal news, showing why the stock isn't only about lawsuits.
Securities fraud class actions pile up Multiple law firms filed class actions alleging ADMA hid a related-party deal and used channel stuffing to inflate revenue, with a lead plaintiff deadline of August 10, 2026. These lawsuits keep legal risk and uncertainty in focus, weighing on the stock.
This is the main new event of the period and directly pressures ADMA's price through legal and reputational risk.
Underlying business still growing ADMA reported 28% year-over-year revenue growth from ASCENIV last quarter and is advancing SG-001, a hyperimmune globulin candidate, while new manufacturing efficiencies expand margins. This shows the core business remains healthy despite the legal cloud.
It provides the real counterweight to the negative legal news, showing why the stock isn't only about lawsuits.